Short double-stranded RNA with immunostimulatory activity: Sequence dependence

Nucleic Acid Therapeutics

Volumn 22, Issue 3, 2012, Pages 196-204

  Kabilova, Tatyana O ^a   Meschaninova, Mariya I ^a   Venyaminova, Alya G ^a   Nikolin, Valery P ^b   Zenkova, Marina A ^a   Vlassov, Valentin V ^a   Chernolovskaya, Elena L ^a  

^a INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DOUBLE STRANDED RNA; IMMUNOSTIMULATING AGENT; IMMUNOSTIMULATING RNA; INTERLEUKIN 6; LIPOFECTAMINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL ADHESION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOSTIMULATION; INHIBITION KINETICS; INNATE IMMUNITY; INTERFERON PRODUCTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MOUTH CARCINOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RNA SEQUENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; MOUTH NEOPLASMS; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING;

EID: 84862316661     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2011.0328     Document Type: Article

References (35)

1. ABLASHI, D.V., BERNEMAN, Z.N., WILLIAMS, M., STRAYER, D.R., KRAMARSKY, B., SUHADOLNIK, R.J., REICHENBACH, N., HILTZGES, P., and KOMAROFF, A.L. (1994). Ampligen inhibits human herpesvirus-6 in vitro. In Vivo 8, 587-591.
2. AKIMOV, I.A., KABILOVA, T.O., VLASSOV, V.V., and CHERNOLOVSKAYA, E.L. (2009). Inhibition of human cancer-cell proliferation by long double-stranded RNAs. Oligonucleotides 19, 31-40.
3. BUI, J.D., and SCHREIBER, R.D. (2007). Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 19, 203-208.
4. BULYCHEV, L.E., PORYVAEV, V.D., RYZHIKOV, A.B., KARPYSHEV, N.N., ALEKSEEVA, A.G., GONCHAROVA, E.P., and PLIASUNOV, I.V. (2003). [An intensification of antiviral and interferon effects of ridostin (an interferon inducer) by cationic liposomes in vitro and in intranasal administration]. Vopr. Virusol. 48, 45-47.
5. CARMICHAEL, J., DeGRAFF, W. G., GAZDAR, A. F., MINNA, J. D. & MITCHELL, J. B. (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47, 936-942.
6. CARSWELL, E.A., OLD, L.J., KASSEL, R.L., GREEN, S., FIORE, N., and WILLIAMSON, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 72, 3666-3670.
7. CURRIE, A.J., VAN DER MOST, R.G., BROOMFIELD, S.A., PROSSER, A.C., TOVEY, M.G., and ROBINSON, B.W. (2008). Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J. Immunol. 180, 1535-1544.
8. DIEBOLD, S.S., MASSACRIER, C., AKIRA, S., PATUREL, C., MOREL, Y., and REIS E SOUSA, C. (2006). Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36, 3256-3267.
9. ESSEY, R.J., MCDOUGALL, B.R., and ROBINSON, W.E., Jr. (2001). Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Res. 51, 189-202.
10. FORSBACH, A., NEMORIN, J.G., MONTINO, C., MULLER, C., SAMULOWITZ, U., VICARI, A.P., JURK, M., MUTWIRI, G.K., KRIEG, A.M., LIPFORD, G. B., and VOLLMER, J. (2008). Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 180, 3729-3738.
11. GONDAI, T., YAMAGUCHI, K., MIYANO-KUROSAKI, N., HABU, Y., and TAKAKU, H. (2008). Short-hairpin RNAs synthesized by T7 phage polymerase do not induce interferon. Nucleic Acids Res. 36, e18.
12. HORNUNG, V., GUENTHNER-BILLER, M., BOURQUIN, C., ABLASSER, A., SCHLEE, M., UEMATSU, S., NORONHA, A., MANOHARAN, M., AKIRA, S., DE, F. A., ENDRES, S., and HARTMANN, G. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270.
13. JUDGE, A., and MACLACHLAN, I. (2008). Overcoming the Innate Immune Response to small interfering RNA. Hum. Gene Ther. 19, 111-124.
14. JUDGE, A.D., SOOD, V., SHAW, J.R., FANG, D., MCCLINTOCK, K., and MACLACHLAN, I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462.
15. KABILOVA, T.O., VLADIMIROVA, A.V., CHERNOLOVSKAYA, E.L., and VLASSOV, V.V. (2006a). Arrest of cancer cell proliferation by dsRNAs. Ann. N. Y. Acad. Sci. 1091, 425-436.
16. KABILOVA, T.O., VLADIMIROVA, A.V., REPKOVA, M.N., VEN'IAMINOVA, A.G., CHERNOLOVSKAIA, E.L., and VLASOV, V.V. (2006b). [Silencing of c-myc gene expression by enzymatically and chemically synthesized siRNAs]. Mol. Biol. (Mosk) 40, 1037-1046.
17. KANG, D.C., GOPALKRISHNAN, R.V., WU, Q., JANKOWSKY, E., PYLE, A.M., and FISHER, P.B. (2002). mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. U. S. A. 99, 637-642.
18. KARIKO, K., NI, H., CAPODICI, J., LAMPHIER, M., and WEISSMAN, D. (2004). mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279, 12542-12550.
19. KISHIMOTO, T. (1989). The biology of interleukin-6. Blood 74, 1-10.
20. KOEBEL, C.M., VERMI, W., SWANN, J.B., ZERAFA, N., RODIG, S.J., OLD, L.J., SMYTH, M.J., and SCHREIBER, R.D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907.
21. KORTYLEWSKI, M., SWIDERSKI, P., HERRMANN, A., WANG, L., KOWOLIK, C., KUJAWSKI, M., LEE, H., SCUTO, A., LIU, Y., YANG, C., et al. (2009). In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27, 925-932.
22. MARQUES, J.T., DEVOSSE, T., WANG, D., ZAMANIAN-DARYOUSH, M., SERBINOWSKI, P., HARTMANN, R., FUJITA, T., BEHLKE, M. A., and WILLIAMS, B. R. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol. 24, 559-565.
23. MASYCHEVA, V.I., DANILENKO, E.D., IGNAT'EV, G.M., FADINA, V.A., and LEVAGINA, G. M. (1997). [Features of formation of antiviral resistance upon local application of the interferon inducer ridostin]. Vopr. Virusol. 42, 126-128.
24. MILLIGAN, J.F., GROEBE, D.R., WITHERELL, G.W., and UHLENBECK, O.C. (1987). Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res. 15, 8783-8798.
25. PERSENGIEV, S.P., ZHU, X., and GREEN, M.R. (2004). Non-specific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA. 10, 12-18.
26. PIPPIG, D.A., HELLMUTH, J.C., CUI, S., KIRCHHOFER, A., LAMMENS, K., LAMMENS, A., SCHMIDT, A., ROTHENFUSSER, S., and HOPFNER, K.P. (2009). The regulatory domain of the RIG-1 family ATPase LGP2 senses double-stranded RNA. Nucleic Acids Res. 37, 2014-2025.
27. POECK, H., BESCH, R., MAIHOEFER, C., RENN, M., TORMO, D., MORSKAYA, S. S., KIRSCHNEK, S., GAFFAL, E., LANDSBERG, J., HELLMUTH, J., et al. (2008). 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14, 1256-1263.
28. PUTHENVEETIL, S., WHITBY, L., REN, J., KELNAR, K., KREBS, J. ., and BEAL, P. . (2006). Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 34, 4900-4911.
29. REYNOLDS, A., ANDERSON, E.M., VERMEULEN, A., FEDOROV, Y., ROBINSON, K., LEAKE, D., KARPILOW, J., MARSHALL, W.S., and KHVOROVA, A. (2006). Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12, 988-993.
30. ROBBINS, M., JUDGE, A., and MACLACHLAN, I. (2009). siRNA and innate immunity. Oligonucleotides 19, 89-102.
31. SCHEGLOVITOVA, O., and ERSHOV, F. (1995). Ridostin inhibits transfer of HIV-1 from abortively infected human umbilical vein endothelial cells to T lymphoblastoid cells. Acta Virol. 39, 189-192.
32. SHANKARAN, V., IKEDA, H., BRUCE, A.T., WHITE, J.M., SWANSON, P.E., OLD, L.J., and SCHREIBER, R.D. (2001). IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111.
33. SHIN, D., KIM, S.I., PARK, M., and KIM, M. (2007). Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem. Biophys. Res. Commun. 364, 436-442.
34. SHREY, K., SUCHIT, A., NISHANT, M., and VIBHA, R. (2009). RNA interference: emerging diagnostics and therapeutics tool. Biochem. Biophys. Res. Commun. 386, 273-277.
35. STEWART, W.E., WIRANOWSKA-STEWART, M., KOISTINEN, V., and CANTELL, K. (1979). Effect of glycosylation inhibitors on the production and properties of human leukocyte interferon. Virology 97, 473-476.